SOPHSOPHiA GENETICS SA
Price
+84%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Nothing alarming, growing in the filings, the market undecided.
- Businessn/a
- SafetyMixed
- Valuationn/a
- GrowthGood
- MarketMixed
We are a cloud-native software technology company in the healthcare space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. We purposefully built a cloud-native software platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. Our platform, SOPHiA DDMTM, standardizes, computes and analyzes digital health data and is used across decentralized locations to break down data silos.
In the company’s own words · 20-F filed Mar 3, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
SOPHiA GENETICS SA (SOPH) reported revenue of $41M in H2 2025 (quarter ended Dec 31, 2025), up 160% from the same quarter a year earlier. That came with a gross margin of 67% and net loss of $39M. For the full year FY2025, revenue was $77M (+19% year on year) and net income −$79M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Health Information Services
The closest names by size in the same industry